Increased urinary type II collagen C-telopeptide levels in Tunisian patients with knee osteoarthritis

Clinical Laboratory

Volumn 58, Issue 3-4, 2012, Pages 209-215

  Eya, Kalai ^a   Bahlous, A ^a   Charni, N ^b   Bouzid, K ^a   Sahli, H ^c   Chelly, M ^c   Meddeb, M ^c   Zouari, B ^a   Abdelmoula, J ^a   Sellami, S ^c  

^a CHARLES NICOLLE HOSPITAL   (Tunisia)

^b Synarc   (France)

^c LA RABTA HOSPITAL   (Tunisia)

Author keywords

Cartilage degradation; Collagen type II; CTX II; Knee; Osteoarthritis

Indexed keywords

C TELOPEPTIDE TYPE 2 COLLAGEN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; JOINT CAVITY; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; X RAY;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CARTILAGE, ARTICULAR; CASE-CONTROL STUDIES; COLLAGEN TYPE II; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PEPTIDE FRAGMENTS; TUNISIA;

EID: 84859839774     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Felson DT. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev 1988;10:1-28. (Pubitemid 18262838)
2. McAlindon TE, Cooper C, Kinwan JR, Dieppe PA. Knee pain and disability in the community. Br J Rheumatol 1992;31:89-92.
3. Ligue Tunisienne Anti-Rhumatismale (LITAR). Département de Médecine Préventive et d'Epidémiologie, Faculté de Médecine de Tunis, Tunisie 2002. Etude de la prévalence de la gonarthrose dans le nord de la tunisie.
4. Abadie E, Ethgen D, Avouac B, et al. Recommendations for the use of new methods to assess the efficacy of disease modifying drugs in the treatment of osteoarthritis. Osteoarth Cart 2004; 12: 263-8. (Pubitemid 38461288)
5. Ravaud P, Giraudeau B, Auleley GR, et al. Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis. Ann Rheum Dis 1998;57:624-9. (Pubitemid 28513142)
6. Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint disease. Arthritis Rheum 2000;43:953-68. (Pubitemid 30368171)
7. Poole AR. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am 2003;29:803-13.
8. Heinegard D, Bayliss M, Lorenzo P. Biochemistry and metabolism of normal and osteoarthritic cartilage. In: Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. Oxford: Oxford University Press; 1998:75-84.
9. Billinghurst RC, Dahlberg L, Ionescu M, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45. (Pubitemid 27163804)
10. Hollander AP, Heathfield TF, Webber C, et al. Increased damage of type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994;93:1722-32. (Pubitemid 24116414)
11. Downs JT, Lane CL, Nestor NB, et al. Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Methods 2001;247:25-34. (Pubitemid 32057041)
12. Garnero P, Ayral X, Rousseau JC, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002;46:2613-24. (Pubitemid 36118924)
13. Birmingham JD, Vilim V, Kraus VB. Collagen biomarkers for arthritis applications. Biomark Insights 2006;2:61-76.
14. Bay-Jensen AC, Sondergaard BC, Christiansen C, Karsdal MA, Madsen SH, Qvist P. Biochemical markers of joint tissue turnover. Assay Drug Dev Technol 2010;8:118-24.
15. Van Spil WE, DeGroot J, Lems WF, Oostveen JC, Lafeber FP. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarth Cart 2010;18:605-12.
16. Garnero P, Delmas PD. Biomarkers in Osteoarthritis. Curr Opin Rheumatol 2003;15:641-6. (Pubitemid 37041406)
17. Kraus VB. Biomarkers in osteoarthritis. Curr Opinion Rheumatol 2005;17:641-6. (Pubitemid 41527828)
18. Lohmander LS. Markers of altered metabolism in osteoarthritis. J Rheumatol 2004;70:28-35. (Pubitemid 38524566)
19. Christgau S, Garnero P, Fledelius C, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-15. (Pubitemid 32823562)
20. Lohmander LS, Atley LM, Pietka TA, Eyre DR. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003;48:3130-9. (Pubitemid 37409324)
21. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
22. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40. (Pubitemid 19037656)
23. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957;16:494-501.
24. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarth and Cart 2009;17:384-9.
25. Reijman M, Hazes JM, Bierma-Zeinstra SM, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004;50:2471-8. (Pubitemid 39062707)
26. Jung M, Christgau S, Lukoschek M, Henriksen D, Richter W. Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis. Pathobiology 2004;71:70-6. (Pubitemid 38056726)
27. Mouritzen U, Christgau S, Lehmann HJ, Tankó LB, Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003;62:332-6. (Pubitemid 36363439)
28. Gabay O, Hall DJ, Berenbaum F, Henrotin Y, Sanchez C. Osteoarthritis and obesity: Experimental models. Joint Bone Spine 2008;75:675-9.
29. Ding C, Cicuttini F, Scott F, Cooley H, Jones G. Knee structural alteration and BMI: a cross-sectional study. Obes Res 2005;13:350-61.
30. Zhai G, Cicuttini F, Ding C, Scott F, Garnero P, Jones G. Correlates of knee pain in younger subjects. Clin Rheumatol 2007;26:75-80. (Pubitemid 46020026)
31. Karsdal MA, Byrjalsen I, Bay-Jensen AC, Henriksen K, Riis BJ, Christiansen C. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis - the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord 2010;11:125.
32. Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum 2005;52:2026-32. (Pubitemid 40994325)
33. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis. Ann Rheum Dis 2001;60:619-26. (Pubitemid 32493990)
34. Garnero P. Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 2006;8:37-44. (Pubitemid 44659358)
35. Meulenbelt I, Kloppenburg M, Kroon HM, et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis 2006;65:360-5. (Pubitemid 43268226)
36. Meulenbelt I, Kloppenburg M, Kroon HM, et al. Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. Osteoart and Cart 2007;15:379-85. (Pubitemid 46381562)
37. Garnero P, Mazières B, Guéguen A, et al. Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol 2005;32:697-703. (Pubitemid 40524704)
38. Garnero P, Charni N, Juillet F, Conrozier T, Vignon E. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2006;65:1639-44. (Pubitemid 44799679)
39. Dahaghin S, Bierma-Zeinstra SM, Reijman M, Pols HA, Hazes JM, Koes BW. Does hand osteoarthritis predict future hip or knee osteoarthritis? Arthritis Rheum 2005;52:3520-7. (Pubitemid 41612219)
40. Gonzalez-Fuentes AM, Green DM, Rossen RD, Ng B. Intraarticular hyaluronic acid increases cartilage breakdown biomarker in patients with knee osteoarthritis. Clin Rheumatol 2010;29:619-24.